Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Centessa Pharmaceuticals (CNTA) Return on Sales (2022 - 2025)

Centessa Pharmaceuticals (CNTA) has disclosed Return on Sales for 4 consecutive years, with 13.17% as the latest value for Q4 2025.

  • Quarterly Return on Sales changed N/A to 13.17% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 13.17% through Dec 2025, changed N/A year-over-year, with the annual reading at 13.17% for FY2025, N/A changed from the prior year.
  • Return on Sales for Q4 2025 was 13.17% at Centessa Pharmaceuticals, up from 16.18% in the prior quarter.
  • The five-year high for Return on Sales was 62.75% in Q3 2024, with the low at 16.18% in Q3 2025.
  • Average Return on Sales over 4 years is 16.65%, with a median of 18.31% recorded in 2024.
  • The sharpest move saw Return on Sales soared 4754bps in 2024, then tumbled -7893bps in 2025.
  • Over 4 years, Return on Sales stood at 19.6% in 2022, then dropped by -27bps to 14.33% in 2023, then soared by 338bps to 62.75% in 2024, then crashed by -121bps to 13.17% in 2025.
  • According to Business Quant data, Return on Sales over the past three periods came in at 13.17%, 16.18%, and 15.36% for Q4 2025, Q3 2025, and Q2 2025 respectively.